Terbinafine Treatment Guidelines

Standard Treatment Durations by Indication

• The British Association of Dermatologists recommends terbinafine 250 mg daily for 12 weeks for toenail onychomycosis and 6 weeks for fingernail onychomycosis, with a strength of recommendation A and level of evidence 1+ 1
• Toenail infections require 12 weeks of continuous therapy, as evidenced by the British Journal of Dermatology 1
• Fingernail infections require 6 weeks of continuous therapy, as recommended by the British Association of Dermatologists 1

Tinea Capitis (Scalp Ringworm) - Pediatric Dosing

• Terbinafine is highly effective against Trichophyton species but significantly less effective against Microsporum species, with griseofulvin being superior for Microsporum infections, as reported by the British Journal of Dermatology 2

Pharmacokinetic Rationale

• Terbinafine persists in the nail for 6 months after treatment completion due to its long half-life and lipophilic properties, allowing for continued fungicidal activity, as described by the British Journal of Dermatology 1

Pre-Treatment and Monitoring Requirements

• Complete blood count is recommended before initiating treatment, particularly in patients with a history of hepatitis, heavy alcohol use, or hematological abnormalities, as advised by the British Journal of Dermatology 1

Absolute Contraindications

• Active or chronic liver disease is an absolute contraindication for terbinafine, as stated by the British Journal of Dermatology 1
• Lupus erythematosus is an absolute contraindication for terbinafine, as reported by the British Journal of Dermatology 2

Critical Safety Warnings

• Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with terbinafine use, as warned by the British Journal of Dermatology 1

Drug Interaction Considerations

• Terbinafine has minimal drug-drug interactions compared to azole antifungals, making it safer for patients on multiple medications, as described by the British Journal of Dermatology 1
• The British Journal of Dermatology notes that terbinafine's interaction with drugs metabolized by cytochrome P450 2D6 (e.g., certain antidepressants, beta-blockers, antiarrhythmics) is a potential concern 1

Practical Prescribing Details

• The British Journal of Dermatology recommends dosing terbinafine at 250 mg once daily for adults 1
• The British Journal of Dermatology notes that terbinafine can be taken with or without food, as absorption is not affected by food intake 1

Terbinafine Treatment Guidelines

Adult Dosing for Onychomycosis

• The British Journal of Dermatology recommends terbinafine is fungicidal against dermatophytes with very low minimum inhibitory concentrations (approximately 0.004 μg/mL) 3
• The British Journal of Dermatology suggests terbinafine has demonstrated superior efficacy compared to itraconazole for dermatophyte onychomycosis, with higher cure rates and lower relapse rates 4

Pediatric Dosing

• The British Journal of Dermatology recommends for children <20 kg: 62.5 mg daily, for children 20-40 kg: 125 mg daily, and for children >40 kg: 250 mg daily (adult dose) 5
• The British Journal of Dermatology suggests duration of 6 weeks for fingernail and 12 weeks for toenail infections 5

Monitoring Recommendations

• The British Journal of Dermatology and Praxis Medical Insights recommend baseline liver function tests (LFTs) and complete blood count (CBC) before starting treatment 4, 6

Contraindications

• Praxis Medical Insights and the British Journal of Dermatology suggest contraindication in patients with active or chronic liver disease and lupus erythematosus 3, 7

Terbinafine Treatment Guidelines

Introduction to Terbinafine Dosing

• The British College of Dermatology recommends prescribing terbinafine 250 mg once daily for 6 weeks for fingernail infections and 12 weeks (up to 16 weeks for severe cases) for toenail infections 8
• For onychomycosis, the standard adult dosing is 250 mg once daily, with treatment duration depending on the severity of the infection and the type of nail affected, according to the British College of Dermatology 8, 9

Standard Adult Dosing by Indication

• The British College of Dermatology suggests that fingernail onychomycosis should be treated with 250 mg once daily for 6 weeks, and toenail onychomycosis with 250 mg once daily for 12-16 weeks 8, 9
• Patients should be re-evaluated 3-6 months after treatment initiation, and additional treatment should be provided if the disease persists, as recommended by the British College of Dermatology 8

Pre-Treatment Requirements

• The British College of Dermatology advises obtaining baseline laboratory tests, including liver function tests and complete blood count, before initiating terbinafine therapy, especially in patients with a history of hepatitis, heavy alcohol use, or hematological abnormalities 8
• Baseline monitoring should also be considered for children, as terbinafine is not licensed for pediatric onychomycosis, according to the British College of Dermatology 8

Absolute Contraindications

• The British College of Dermatology states that terbinafine should not be prescribed in patients with active or chronic liver disease 8

Drug Interactions

• The British College of Dermatology notes that terbinafine has minimal drug-drug interactions compared to azole antifungals, making it safer for patients on multiple medications 8
• The only potentially significant interaction is with drugs metabolized by cytochrome P450 2D6 isoenzyme, including certain antidepressants, beta-blockers, and antiarrhythmics, as reported by the British College of Dermatology 8

Common Adverse Effects

• The British College of Dermatology reports that the most common side effects of terbinafine include gastrointestinal complaints, dermatological events, and headache, with an incidence of serious adverse events of only 0.04% 8

Why Terbinafine is First-Line

• The British College of Dermatology recommends terbinafine as first-choice therapy for dermatophyte onychomycosis based on its superior efficacy and tolerability 8, 9
• Terbinafine is fungicidal against dermatophytes with very low minimum inhibitory concentrations, and has been shown to have higher complete cure rates and lower relapse rates compared to itraconazole, according to the British College of Dermatology 8, 9

Resuming Oral Treatment for Onychomycosis after Terbinafine

Introduction to Treatment Resumption

• The British Journal of Dermatology recommends reevaluating the patient 3 to 6 months after the initial treatment begins, and if the disease persists, a new treatment can be started without additional waiting period 10

Rationale for Treatment

• The British Journal of Dermatology suggests that terbinafine remains detectable in nails for a prolonged period after treatment cessation, allowing for continued antifungal activity 10

Decision Algorithm for Resuming Treatment

• The British Journal of Dermatology advises evaluating the patient now (3 months post-treatment) or waiting up to 6 months to determine the therapeutic response, including mycological analysis and clinical examination of the nail 10
• If therapeutic failure is confirmed, the British Journal of Dermatology recommends immediately resuming oral treatment without additional waiting period, with terbinafine 250 mg per day remaining the first-line treatment for dermatophytes 10

Important Considerations Before Resuming Treatment

• The British Journal of Dermatology suggests that pre-treatment checks, including liver function tests and complete blood count, are obligatory, especially in patients with a history of hepatitis, excessive alcohol consumption, or hematological abnormalities 10
• The British Journal of Dermatology recommends confirming that the infection is due to a dermatophyte, as terbinafine is superior for dermatophytes but less effective against Candida 10

Alternatives for Repeated Failure

• The British Journal of Dermatology suggests that itraconazole becomes the second-line alternative if the second terbinafine treatment fails, with a dosage of 200 mg per day for 12 weeks or 400 mg per day for 1 week per month for 3 cycles 10
• The British Journal of Dermatology recommends considering fluconazole 450 mg per week for at least 6 months if there is intolerance to terbinafine and itraconazole, although it is less effective 10

Terbinafine Treatment Guidelines

Adult Dosing and Efficacy

• The British Association of Dermatologists designates terbinafine as first-line treatment for dermatophyte onychomycosis with a strength of recommendation A and level of evidence 1+, generally preferred over itraconazole due to superior efficacy and lower relapse rates 11
• Terbinafine is dosed at 250 mg once daily, with treatment duration of 6 weeks for fingernail onychomycosis and 12 weeks (up to 16 weeks for severe cases) for toenail onychomycosis 11

Pediatric Considerations

• Terbinafine is not FDA-approved for pediatric onychomycosis, though it is the only oral antifungal licensed for use in children in some jurisdictions 12
• Griseofulvin remains the only FDA-approved oral antifungal for pediatric onychomycosis at 10 mg/kg per day 12

Pre-Treatment Requirements and Monitoring

• Liver function tests (ALT and AST) are required before treatment initiation, particularly in patients with a history of hepatitis or liver disease 11
• Complete blood count is also required before treatment initiation 11
• Patients with pre-existing deranged liver function tests require monitoring throughout treatment 11

Adverse Effects and Warnings

• Gastrointestinal disturbances (49% of reported side effects): nausea, diarrhea, abdominal pain 11
• Headache 11
• Taste disturbance 11
• Subacute lupus-like syndrome 11
• Psoriasis aggravation 11

Special Populations and Drug Interactions

• Itraconazole is preferred over terbinafine for Candida onychomycosis due to broader antimicrobial coverage 13

Safe Concurrent Use of Steroids and Terbinafine

Rationale for Safety

• Terbinafine has minimal drug-drug interactions compared to azole antifungals, making it one of the safest systemic antifungals for patients on multiple medications, as recommended by the British Journal of Dermatology guidelines 14, 15.
• The only potentially significant interactions with terbinafine involve drugs metabolized by cytochrome P450 2D6, not corticosteroids, according to the British Journal of Dermatology 15.

Important Monitoring Considerations

• Baseline liver function tests and complete blood count were obtained before starting terbinafine, as suggested by the British Journal of Dermatology guidelines 14.
• Monitor liver function tests if the patient has a history of hepatitis, heavy alcohol use, or develops symptoms suggestive of hepatotoxicity, as recommended by the British Journal of Dermatology 14.
• The most common adverse effects of terbinafine are gastrointestinal complaints, headache, and taste disturbance—none of which are exacerbated by corticosteroids, according to the British Journal of Dermatology 14.

Practical Prescribing Guidance

• Prescribe the corticosteroid as clinically indicated for wrist inflammation without dose adjustment of terbinafine, as recommended by the British Journal of Dermatology guidelines 14, 15.
• Continue terbinafine 250 mg daily for the full treatment duration, as suggested by the British Journal of Dermatology 14.

Key Clinical Caveat

• The primary concern with terbinafine is hepatotoxicity, not drug interactions, and active or chronic liver disease is an absolute contraindication to terbinafine, as recommended by the British Journal of Dermatology guidelines 14.

Terbinafine Use in Children

Introduction to Terbinafine Therapy

• The British Association of Dermatologists recommends terbinafine for children ≥4 years of age, specifically for tinea capitis (scalp ringworm), with careful attention to the causative organism and formulation availability 16, 17

FDA Approval Status and Formulation Considerations

• Terbinafine oral granules are FDA-approved for children ≥4 years of age in the United States, specifically for tinea capitis (scalp ringworm) 16
• The granule formulation offers practical advantages for pediatric administration but remains unlicensed in the UK 16, 17

Primary Indication: Tinea Capitis (Scalp Ringworm)

• The effectiveness of terbinafine in a 4-year-old depends entirely on which fungus is causing the infection: for Trichophyton species, terbinafine is highly effective with 2-4 weeks of treatment 16, 17
• For Microsporum species, griseofulvin is superior and should be used instead—terbinafine shows poor efficacy 16, 17

Clinical Algorithm for Tinea Capitis in a 4-Year-Old

• Obtain scalp scrapings/hair pluck for microscopy and culture to identify the causative organism 16
• Choose initial therapy based on local epidemiology: in regions where Trichophyton tonsurans predominates, start terbinafine 16

Safety Profile in 4-Year-Olds

• Terbinafine is well-tolerated in children with minimal side effects: gastrointestinal disturbances and rashes occur in <8% of pediatric patients 16, 17

Practical Prescribing Details

• The granule formulation improves palatability and compliance compared to tablets 16
• Treatment duration is significantly shorter than griseofulvin (2-4 weeks vs. 6-18 weeks), improving compliance 16